Keywords: merrimack, completes, enrollment, mm-093, trial, rheumatoid, arthritis
Merrimack completes enrollment of MM-093 trial for rheumatoid arthritis
Article | 30 August 2004
USA-based Merrimack Pharmaceuticals has completed patient enrollment fora Phase IIa pilot clinical trial of its immunomodulatory drug candidate, MM-093, a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
